{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:44:42Z","timestamp":1782733482887,"version":"3.54.5"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":179,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Skin Cancer"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Basal cell carcinomas (BCCs) with aggressive histology are infiltrative, destructive, aggressive, and metastatic tumors. Aggressive variants include morpheaform, infiltrative, metatypical or basosquamous, micronodular, and mixed subtypes. Selecting the appropriate treatment is crucial to eliminate this type of tumor and avoid complications such as mutilation and deformities when located in the facial region, as well as tumor recurrence. Interferons may represent a therapeutic option because of their curative potential and long\u2010term cosmetic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>A descriptive, longitudinal, observational case\u2010series study was conducted, including patients with a histopathological diagnosis of aggressive BCC. Perilesional HeberFERON was administered for three weeks, and patients were then followed for 5\u2009years. The main outcome variables were cure at 16\u2009weeks and recurrence at 5\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty\u2010three patients were included, and one discontinued treatment. After therapy, 14 (63.6%) patients achieved cure (complete response [CR]). Those who did not achieve a CR underwent surgery and were declared cured. All 22 patients were followed for five years; two (9.0%) were lost to follow\u2010up. Survival analysis showed that 86.4% (95% CI, 74%\u201399%) had the probability of remaining recurrence\u2010free at five years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HeberFERON can be considered a first\u2010line treatment for BCC with aggressive histology and as a therapy prior to subsequent surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/jskc\/8852284","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:51:43Z","timestamp":1782730303000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Five\u2010Year Follow\u2010Up of Patients With Histologically Aggressive Basal Cell Carcinoma Treated With Interferon"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6889-5299","authenticated-orcid":false,"given":"Vladimir Sanchez","family":"Linares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-653X","authenticated-orcid":false,"given":"Vicente Eloy Fardales","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-9137","authenticated-orcid":false,"given":"Iraldo Bello","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.34119\/bjhrv6n4-212"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00201-8"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000526478"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.01.026"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30110720"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071636"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3710"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121943"},{"key":"e_1_2_11_9_2","article-title":"Resultados Del Uso De Heberferon En Pacientes Con Carcinoma Basocelular De Alto Riesgo En Matanzas","volume":"45","author":"Berm\u00fadez Sa\u00f1udo D.","year":"2023","journal-title":"Rev M\u00e9d Electr\u00f3n"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.04.007"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.14312\/2052-4994.2013-36"},{"key":"e_1_2_11_12_2","article-title":"Heberferon En El Carcinoma Basocelular Periocular","volume":"23","author":"S\u00e1nchez Linares V.","year":"2021","journal-title":"Serie de Casos. Gac M\u00e9d espirit"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_11_14_2","article-title":"Basal Cell Carcinoma Treated With Heberferon. A Real World Retrospective Study","volume":"6","author":"Mart\u00ednez Su\u00e1rez C.","year":"2021","journal-title":"Clinical Oncology"},{"key":"e_1_2_11_15_2","unstructured":"Duncan RobertsY. Garcia VegaY. Collazo CaballeroS.et al. Five Years Follow-Up of Patients With Non-Melanoma Skin Cancer Treated With Heberferon https:\/\/www.medrxiv.org\/content\/10.1101\/2022.02.07.22270604v1.full.pdf."},{"key":"e_1_2_11_16_2","article-title":"Heberferon En El Tratamiento De Pacientes Con Carcinoma Basocelular En Zona De Alto Riesgo","volume":"39","author":"S\u00e1nchez Linares V.","year":"2023","journal-title":"Revista Cubana de Medicina General Integral"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20174867"},{"key":"e_1_2_11_18_2","first-page":"S45","article-title":"Diferencias y Similitudes Dermatosc\u00f3picas Del Carcinoma Basocelular Agresivo y Del Carcinoma De C\u00e9lulas Escamosas","volume":"68","author":"Qui\u00f1ones Venegas R.","year":"2024","journal-title":"Dermatolog\u00eda Revista Mexicana"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59020349"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70192-8"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70276-n"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670320053006"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246688"},{"key":"e_1_2_11_24_2","article-title":"Caracterizaci\u00f3n De Pacientes Con Carcinoma Basocelular Tratados Con Heberferon","volume":"24","author":"Ferr\u00e1 Torres T.","year":"2020","journal-title":"Arch m\u00e9d Camag\u00fcey"},{"key":"e_1_2_11_25_2","article-title":"Efectividad Del Heberferon En El Tratamiento Del Carcinoma Basocelular","volume":"46","author":"Marrero G. G.","year":"2021","journal-title":"Rev Electr\u00f3n Dr Zoilo E Marinello Vidaurreta"},{"key":"e_1_2_11_26_2","article-title":"Carcinoma Basocelular Periocular Tratado Con Una Mezcla De Interferones En La Atenci\u00f3n Primaria","volume":"41","author":"Fern\u00e1ndez Martori M.","year":"2025","journal-title":"Revista Cubana de Medicina General Integral"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1996.tb04040.x"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.15406\/jdc.2022.06.00220"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.08.009"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70158-c"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525100-00005"},{"key":"e_1_2_11_33_2","article-title":"Retrospective Study of Periocular Non-Melanoma Skin Cancer Treated With the Combination of IFN Alpha2b and Gamma (Heberpag)","volume":"6","author":"Garc\u00eda-Vega Y.","year":"2015","journal-title":"Journal of Clinical & Experimental Ophthalmology"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-262"},{"key":"e_1_2_11_35_2","first-page":"381","article-title":"Treatment of Basal Cell Carcinoma of the Nasal Pyramid With Intralesional Interferon Alfa-2b","volume":"9","author":"Fern\u00e1ndez-Vozmediano J. M.","year":"2010","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72732-x"}],"container-title":["Journal of Skin Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/jskc\/8852284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/jskc\/8852284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/jskc\/8852284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:51:48Z","timestamp":1782730308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/jskc\/8852284"}},"subtitle":[],"editor":[{"given":"Carmen","family":"Cantisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/jskc\/8852284"],"URL":"https:\/\/doi.org\/10.1155\/jskc\/8852284","archive":["Portico"],"relation":{},"ISSN":["2090-2905","2090-2913"],"issn-type":[{"value":"2090-2905","type":"print"},{"value":"2090-2913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8852284"}}